Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

This publication has 14 references indexed in Scilit:

• Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials
  Clinical Infectious Diseases, 2006
• Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir
  Antiviral Research, 2005
• Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers
  HIV Research & Clinical Practice, 2004
• Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group
  The Journal of Infectious Diseases, 2004
• Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
  The Lancet, 2004
• A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1???Infected Patients
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
• Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term Strategies
  Clinical Infectious Diseases, 2000
• In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
  AIDS, 2000
• Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class
  Journal of Medicinal Chemistry, 1998
• Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
  Antimicrobial Agents and Chemotherapy, 1997